|Day's Range||85.73 - 86.21|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||32.24|
|Dividend & Yield||2.72 (3.15%)|
|1y Target Est||N/A|
Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis. The approval was based on a development programme that demonstrated that Erelzi, a biosimilar of the drug also known as etanercept, matches its reference medicine in terms of safety, efficacy, and quality, Sandoz said in a statement on Tuesday.
The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk
Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.